Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics

References

• Kuperberg G, Heckers S. Schizophrenia and cognitive function. Curr Opin Neurobiol. 2000;10:205–210.10753790
   PubMed Web of Science ®Google Scholar
• Zhang W, Amos TB, Gutkin SW, Lodowski N, Giegerich E, Joshi K. A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States. Clinicoecon Outcomes Res. 2018;10:309–320. doi:10.2147/CEOR.S15630829922078
   PubMed Web of Science ®Google Scholar
• Zhang C, Li Z, Shao Y, et al. Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. J Mol Neurosci. 2011;43:406–411. doi:10.1007/s12031-010-9458-220938755
   PubMed Web of Science ®Google Scholar
• Zhang C, Fang X, Yao P, et al. Metabolic adverse effects of olanzapine on cognitive dysfunction: a possible relationship between BDNF and TNF-alpha. Psychoneuroendocrinology. 2017;81:138–143. doi:10.1016/j.psyneuen.2017.04.01428477447
   PubMed Web of Science ®Google Scholar
• Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40:771–781. doi:10.1007/s40264-017-0543-028585153
   PubMed Web of Science ®Google Scholar
• Jeon SW, Kim YK. Unresolved issues for utilization of atypical antipsychotics in schizophrenia: antipsychotic polypharmacy and metabolic syndrome. Int J Mol Sci. 2017;18(10): 2174.
   Web of Science ®Google Scholar
• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448. doi:10.1146/annurev-clinpsy-032813-15365724313570
   PubMed Web of Science ®Google Scholar
• Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl. 2004;47:S67–S71.15056596
   PubMedGoogle Scholar
• Lone S, Lone K, Khan S, Pampori RA. Pampori, Assessment of metabolic syndrome in Kashmiri population with type 2 diabetes employing the standard criteria’s given by WHO, NCEPATP III and IDF. J Epidemiol Glob Health. 2017;7:235–239. doi:10.1016/j.jegh.2017.07.00429110863
   PubMed Web of Science ®Google Scholar
• Meyer JM. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. J Clin Psychiatry. 2007;68:28–33.
   PubMed Web of Science ®Google Scholar
• Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017;47:1030–1040. doi:10.1017/S003329171600336628032535
   PubMed Web of Science ®Google Scholar
• Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol. 2015;12:267–277. doi:10.1038/nrcardio.2014.22325583619
   PubMed Web of Science ®Google Scholar
• Kaffashian S, Dugravot A, Elbaz A, et al. Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk scores. Neurology. 2013;80:1300–1306.23547265
   PubMed Web of Science ®Google Scholar
• MacKenzie NE, Kowalchuk C, Agarwal SM, et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018;9:622. doi:10.3389/fpsyt.2018.0062230568606
   PubMed Web of Science ®Google Scholar
• Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80(1):9–18. doi:10.1016/j.schres.2005.07.01516125372
   PubMed Web of Science ®Google Scholar
• Goughari AS, Mazhari S, Pourrahimi AM, Sadeghi MM, Nakhaee N. Associations between components of metabolic syndrome and cognition in patients with schizophrenia. J Psychiatr Pract. 2015;21(3):190–197. doi:10.1097/PRA.000000000000006525955261
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. doi:10.1038/nature0548517167474
   PubMed Web of Science ®Google Scholar
• Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37:1901–1911. doi:10.1016/j.psyneuen.2012.04.00122541717
   PubMed Web of Science ®Google Scholar
• Madeshiya AK, Singh S, Dwivedi S, Konwar R, Natu SM, Ghatak A. Association of IL-10 gene (−1082A>G, −819C>T and −592C>A) polymorphism and its serum level with metabolic syndrome of north Indian subjects. J Genet. 2017;96:53–64.28360390
   PubMed Web of Science ®Google Scholar
• Neelamekam S, Nurjono M, Lee J. Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis. Clin Psychopharmacol Neurosci. 2014;12:209–214. doi:10.9758/cpn.2014.12.3.20925598824
   PubMed Web of Science ®Google Scholar
• Klemettila JP, Kampman O, Seppala N, et al. Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Res. 2014;218:277–283. doi:10.1016/j.psychres.2014.04.04924837425
   PubMed Web of Science ®Google Scholar
• Contreras-Shannon V, Heart DL, Paredes RM, et al. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One. 2013;8:e59012. doi:10.1371/journal.pone.005901223527073
   PubMed Web of Science ®Google Scholar
• Sirota P, Hadi E, Djaldetti M, Bessler H. Difference in inflammatory cytokine production by mononuclear cells from obese and non-obese schizophrenic patients. Acta Psychiatr Scand. 2015;132:301–305. doi:10.1111/acps.1239625627461
   PubMed Web of Science ®Google Scholar
• Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20:310–319. doi:10.1076/jcen.20.3.310.8239845158
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wu W, Wang J, Feng W, Wu X, Li C. Reliability and validity of the repeatable battery for the assessment of neuropsychological status in community-dwelling elderly. Arch Med Sci. 2011;7:850–857. doi:10.5114/aoms.2011.2556122291831
   PubMed Web of Science ®Google Scholar
• Cai J, Zhu Y, Zhang W, Wang Y, Zhang C. Comprehensive family therapy: an effective approach for cognitive rehabilitation in schizophrenia. Neuropsychiatr Dis Treat. 2015;11:1247–1253. doi:10.2147/NDT.S8356926056456
   PubMed Web of Science ®Google Scholar
• Fang X, Chen Y, Wang Y, Zhang C. Identification of risk factors for suicidal ideation in patients with schizophrenia. Psychiatry Res. 2018;271:195–199. doi:10.1016/j.psychres.2018.11.05130500709
   PubMed Web of Science ®Google Scholar
• Zhou H, Guo ZR, Yu LG, et al. Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. Diabetes Res Clin Pract. 2010;90:319–325. doi:10.1016/j.diabres.2010.09.00120934770
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen M, Chen J, et al. Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Psychopharmacology (Berl). 2014;231:2211–2218. doi:10.1007/s00213-013-3410-424448899
   PubMed Web of Science ®Google Scholar
• Zheng J, Shi Y, Xiong L, et al. The expression of IL-6, TNF-alpha, and MCP-1 in respiratory viral infection in acute exacerbations of chronic obstructive pulmonary disease. J Immunol Res. 2017;2017:8539294. doi:10.1155/2017/597457428352642
   PubMed Web of Science ®Google Scholar
• Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull. 2013;39:306–318. doi:10.1093/schbul/sbr14822207632
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347. doi:10.1002/wps.2025226407790
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Z, Zhao G, Wang F, Fang Y. Identification of IL6 as a susceptibility gene for major depressive disorder. Sci Rep. 2016;6:31264. doi:10.1038/srep3126427502736
   PubMed Web of Science ®Google Scholar
• Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring). 2016;14:2127–2131. doi:10.1038/oby.2006.248
   Web of Science ®Google Scholar
• Ingelsson E, Hulthe J, Lind L. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest. 2008;38:502–509. doi:10.1111/j.1365-2362.2008.01962.x18489581
   PubMed Web of Science ®Google Scholar
• Pacheco-Lopez G, Giovanoli S, Langhans W, Meyer U. Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia. Schizophr Bull. 2013;39:319–329. doi:10.1093/schbul/sbr17822186136
   PubMed Web of Science ®Google Scholar
• Bian AL, Hu HY, Rong YD, Wang J, Wang J-X, Zhou X-Z. A study on relationship between elderly sarcopenia and inflammatory factors IL-6 and TNF-alpha. Eur J Med Res. 2017;22:25. doi:10.1186/s40001-017-0266-928701179
   PubMed Web of Science ®Google Scholar
• Diaz-Ruiz M, Martinez-Triguero ML, Lopez-Ruiz A, et al. Metabolic disorders and inflammation are associated with familial combined hyperlipemia. Clin Chim Acta. 2019;490:194-199.
   Web of Science ®Google Scholar
• Venkatesh BK, Thirthalli J, Naveen MN, et al. Sex difference in age of onset of schizophrenia: findings from a community-based study in India. World Psychiatry. 2018;7:173–176. doi:10.1002/j.2051-5545.2008.tb00191.x
   Google Scholar
• Ran MS, Mao WJ, Chan CL, et al. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study. Br J Psychiatry. 2015;206:283–288. doi:10.1192/bjp.bp.113.13973325573398
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen DC, Tan YL, et al. Gender difference in association of cognition with BDNF in chronic schizophrenia. Psychoneuroendocrinology. 2014;48:136–146. doi:10.1016/j.psyneuen.2014.06.00424999831
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Qi LY, et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl). 2009;204:177–184. doi:10.1007/s00213-008-1447-619139851
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen M, Wu Z, et al. Association study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results. PLoS One. 2013;8:e72652. doi:10.1371/journal.pone.007265223967328
   PubMed Web of Science ®Google Scholar
• Chen S, Broqueres-You D, Yang G, et al. Male sex may be associated with higher metabolic risk in first-episode schizophrenia patients: a preliminary study. Asian J Psychiatr. 2016;21:25–30. doi:10.1016/j.ajp.2015.12.00127208452
   PubMed Web of Science ®Google Scholar
• Kraemer S, Minarzyk A, Forst T, Kopf D, Hundemer H-P. Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics – results from a German observational study. BMC Psychiatry. 2011;11:173. doi:10.1186/1471-244X-11-17322044502
   PubMed Web of Science ®Google Scholar
• Pepe H, Balci SS, Revan S, Akalin PP, Kurtoğlu F. Comparison of oxidative stress and antioxidant capacity before and after running exercises in both sexes. Gend Med. 2009;6:587–595. doi:10.1016/j.genm.2009.10.00120114009
   PubMed Web of Science ®Google Scholar
• Harish G, Venkateshappa C, Mahadevan A, Pruthi N, Srinivas Bharath MM, Shankar SK. Glutathione metabolism is modulated by postmortem interval, gender difference and agonal state in postmortem human brains. Neurochem Int. 2011;59:1029–1042. doi:10.1016/j.neuint.2011.08.02421945455
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Khan A, Kaushik S, et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res. 2012;142:171–176. doi:10.1016/j.schres.2012.09.01923106932
   PubMed Web of Science ®Google Scholar